These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis. Yang Y; Luo H; Zheng XL; Ge H Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281 [TBL] [Abstract][Full Text] [Related]
23. [Application of Immune Checkpoint Inhibitors in EGFR Mutant Advanced Non-small Cell Lung Cancer]. Zheng Y; Jiang W; Li J; Dai L; Chen D; Li Y; Huang L; Wang M Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):671-677. PubMed ID: 36172732 [TBL] [Abstract][Full Text] [Related]
24. EGFR mutations induce the suppression of CD8 Huang H; Zhu X; Yu Y; Li Z; Yang Y; Xia L; Lu S J Transl Med; 2024 Jul; 22(1):653. PubMed ID: 39004699 [TBL] [Abstract][Full Text] [Related]
25. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Chen H; Han KD; He ZJ; Huang YS Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149 [TBL] [Abstract][Full Text] [Related]
26. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer. Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K Front Immunol; 2021; 12():646874. PubMed ID: 33927719 [TBL] [Abstract][Full Text] [Related]
27. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC). Yoneda K; Imanishi N; Ichiki Y; Tanaka F J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736 [TBL] [Abstract][Full Text] [Related]
28. Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer. He D; Wang L; Xu J; Zhao J; Bai H; Wang J Front Immunol; 2023; 14():1265865. PubMed ID: 37915579 [TBL] [Abstract][Full Text] [Related]
29. Exploring the relationship between intestinal microbiota and immune checkpoint inhibitors in the treatment of non-small cell lung cancer: insights from the "lung and large intestine stand in exterior-interior relationship" theory. Li L; Zhong H; Wang Y; Pan Z; Xu S; Li S; Zeng G; Zhang W; Li J; He L Front Cell Infect Microbiol; 2024; 14():1341032. PubMed ID: 38415012 [TBL] [Abstract][Full Text] [Related]
30. Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer. Zhou Q; Liu X; Li J; Tong B; Xu Y; Chen M; Liu X; Gao X; Shi Y; Zhao J; Zhong W; Wang M Thorac Cancer; 2023 Feb; 14(5):470-478. PubMed ID: 36630992 [TBL] [Abstract][Full Text] [Related]
31. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079 [TBL] [Abstract][Full Text] [Related]
32. Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer. Cheng W; Kang K; Zhao A; Wu Y J Hematol Oncol; 2024 Jul; 17(1):54. PubMed ID: 39068460 [TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application. Xiao G; Liu Z; Gao X; Wang H; Peng H; Li J; Yang L; Duan H; Zhou R Immunotherapy; 2021 Aug; 13(12):1031-1051. PubMed ID: 34231370 [TBL] [Abstract][Full Text] [Related]
34. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression. Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391 [TBL] [Abstract][Full Text] [Related]
35. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study). Wang Y; Deng L; Wang J; Zhang T; Wang W; Wang X; Liu W; Wu Y; Lv J; Feng Q; Zhou Z; Wang J; Wang L; Wang Z; Bi N Front Immunol; 2023; 14():1341584. PubMed ID: 38288117 [TBL] [Abstract][Full Text] [Related]
36. Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer. Li S; Zhang C; Pang G; Wang P Front Immunol; 2020; 11():603157. PubMed ID: 33178229 [TBL] [Abstract][Full Text] [Related]
37. Effect of PD-L1 Expression for the PD-1/L1 Inhibitors on Non-small Cell Lung Cancer: A Meta-analysis Based on Randomised Controlled Trials. Xu Z; Liang J; Fu R; Yang L; Xin Chen Y; Ren W; Lu Y; Qiu X; Gu Q Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):640-651. PubMed ID: 37563075 [TBL] [Abstract][Full Text] [Related]
38. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects. Peters S; Paz-Ares L; Herbst RS; Reck M J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858709 [TBL] [Abstract][Full Text] [Related]
39. The cutting-edge progress of immune-checkpoint blockade in lung cancer. Zhou F; Qiao M; Zhou C Cell Mol Immunol; 2021 Feb; 18(2):279-293. PubMed ID: 33177696 [TBL] [Abstract][Full Text] [Related]
40. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B Front Immunol; 2020; 11():1956. PubMed ID: 32983126 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]